Selepressin
Also known as: FE 202158
An investigational selective vasopressin V1a receptor agonist studied for septic shock. Not approved; development stopped after the SEPSIS-ACT trial.
Last updated
Mechanism of Action
Selepressin is a synthetic peptide analog of vasopressin designed to act selectively on the V1a receptor on vascular smooth muscle, causing vasoconstriction. Unlike vasopressin, it has little activity at V2 receptors, which mediate water retention and release of clotting factors. The hypothesis was that selective V1a agonism would restore blood pressure in septic shock while limiting fluid overload and vascular leak.
- Half-life
- Not well established
- Administration Routes
- Intravenous
- Research Status
- Clinical
Reported Benefits
- Studied as a vasopressor to replace norepinephrine in septic shock
- Phase 2a data suggested it could maintain blood pressure with less norepinephrine
- Phase 2b/3 SEPSIS-ACT did not improve ventilator- and vasopressor-free days
Potential Side Effects
- Investigational: safety profile limited to trial data
- Ischemic events were monitored as a vasoconstrictor class risk
- No safety advantage established over placebo in SEPSIS-ACT
Common Dosing
No approved dose; trial regimens used continuous intravenous infusions in the ICU at weight-based rates in nanograms per kilogram per minute, titrated against norepinephrine requirements. It is not available outside the completed trials.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Investigational: not established
No documented stacking partners for Selepressin yet.
- View
Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial
2019
- View
Selepressin, a novel selective vasopressin V(1A) agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients
2017